Materiały źródłowe

• #1 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  Treatment for this condition depends on the cause. […] If you’ve had significant blood loss from a recent surgery or an injury, your elevated platelet count might resolve on its own. […] If you have a chronic infection or an inflammatory disease, your platelet count likely will remain high until the condition is under control. In most cases, your platelet count will return to normal after the cause is resolved. […] If you’ve had your spleen removed, you might have lifelong thrombocytosis, but you’re unlikely to need treatment. […] People with this condition who have no signs or symptoms usually don’t need treatment. You might need to take daily, low-dose aspirin to help thin your blood if you’re at risk of blood clots. Don’t take aspirin without checking with your health care team.

• #2 Secondary Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560810/

  Thrombocytosis, or thrombocythemia, occurs when the platelet count exceeds 450,000/L of blood. […] Treatment focuses on addressing the underlying cause, which typically resolves the elevated platelet count. Antiplatelet therapy is generally unnecessary unless the platelet count is extremely high or there is a risk of thrombosis. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. […] Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #3 Secondary Thrombocytosis Treatment & Management: Medical Care, Long-Term Monitoring

  https://emedicine.medscape.com/article/206811-treatment

  The primary treatment of secondary thrombocytosis (reactive thrombocytosis) should address the underlying cause of the thrombocytosis. For example, iron supplementation may normalize platelet counts in patients with thrombocytosis secondary to inflammatory bowel disease. […] In general, no treatment is indicated to directly reduce the platelet count. […] However, for patients with platelet counts in excess of 1,000,000/L, daily low-dose aspirin may be considered to minimize the rare development of stroke or thrombosis. […] A case report describes effective use of plateletpheresis for treatment of an internal carotid artery thrombus resulting in a right middle cerebral artery stroke, in a patient with previously undiagnosed reactive thrombocytosis (platelet count of 1,014,000/L) secondary to iron deficiency anemia. […] In patients with secondary thrombocytosis (reactive thrombocytosis) for whom the causal condition has not been identified, maintain careful outpatient monitoring with physical examination and routine laboratory tests to exclude the development of an occult disorder (eg, malignancy).

• #4 Secondary Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560810/

  Thrombocytosis, or thrombocythemia, occurs when the platelet count exceeds 450,000/L of blood. […] Treatment focuses on addressing the underlying cause, which typically resolves the elevated platelet count. Antiplatelet therapy is generally unnecessary unless the platelet count is extremely high or there is a risk of thrombosis. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. […] Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #5 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  Treatment for this condition depends on the cause. […] If you’ve had significant blood loss from a recent surgery or an injury, your elevated platelet count might resolve on its own. […] If you have a chronic infection or an inflammatory disease, your platelet count likely will remain high until the condition is under control. In most cases, your platelet count will return to normal after the cause is resolved. […] If you’ve had your spleen removed, you might have lifelong thrombocytosis, but you’re unlikely to need treatment. […] People with this condition who have no signs or symptoms usually don’t need treatment. You might need to take daily, low-dose aspirin to help thin your blood if you’re at risk of blood clots. Don’t take aspirin without checking with your health care team.

• #6 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  Treatment for this condition depends on the cause. […] If you’ve had significant blood loss from a recent surgery or an injury, your elevated platelet count might resolve on its own. […] If you have a chronic infection or an inflammatory disease, your platelet count likely will remain high until the condition is under control. In most cases, your platelet count will return to normal after the cause is resolved. […] If you’ve had your spleen removed, you might have lifelong thrombocytosis, but you’re unlikely to need treatment. […] People with this condition who have no signs or symptoms usually don’t need treatment. You might need to take daily, low-dose aspirin to help thin your blood if you’re at risk of blood clots. Don’t take aspirin without checking with your health care team.

• #7 Secondary Thrombocytosis Treatment & Management: Medical Care, Long-Term Monitoring

  https://emedicine.medscape.com/article/206811-treatment

  The primary treatment of secondary thrombocytosis (reactive thrombocytosis) should address the underlying cause of the thrombocytosis. For example, iron supplementation may normalize platelet counts in patients with thrombocytosis secondary to inflammatory bowel disease. […] In general, no treatment is indicated to directly reduce the platelet count. […] However, for patients with platelet counts in excess of 1,000,000/L, daily low-dose aspirin may be considered to minimize the rare development of stroke or thrombosis. […] A case report describes effective use of plateletpheresis for treatment of an internal carotid artery thrombus resulting in a right middle cerebral artery stroke, in a patient with previously undiagnosed reactive thrombocytosis (platelet count of 1,014,000/L) secondary to iron deficiency anemia. […] In patients with secondary thrombocytosis (reactive thrombocytosis) for whom the causal condition has not been identified, maintain careful outpatient monitoring with physical examination and routine laboratory tests to exclude the development of an occult disorder (eg, malignancy).

• #8 High Platelet Count (Thrombocytosis): Symptoms, Causes and Treatment

  https://www.citizenshospitals.com/blogs/high-platelet-count-thrombocytosis-symptoms-causes-and-treatment

  Controlling Inflammation: Medications such as corticosteroids or disease-modifying anti-rheumatic drugs (DMARDs) may be prescribed to manage inflammatory conditions. […] Iron Supplementation: If iron deficiency is identified as the cause, iron supplements or dietary changes may be recommended to restore normal levels and reduce platelet counts. […] Monitoring: Regular follow-up appointments to monitor platelet counts and assess the effectiveness of treatment strategies.

• #9 High Platelet Count (Thrombocytosis): Symptoms, Causes and Treatment

  https://www.citizenshospitals.com/blogs/high-platelet-count-thrombocytosis-symptoms-causes-and-treatment

  Managing Primary Thrombocythemia […] For individuals diagnosed with essential thrombocythemia, treatment options may include: […] Medications: […] Low-dose Aspirin: Often prescribed to reduce the risk of blood clots in individuals with elevated platelet counts. […] Cytoreductive Therapy: Medications such as hydroxyurea, anagrelide, or interferon may be used to lower platelet counts and reduce the risk of complications. […] Regular Monitoring: Ongoing monitoring of blood counts and assessing for any signs of complications. […] Treating Secondary Thrombocytosis […] Secondary thrombocytosis is typically treated by addressing the underlying condition causing the elevated platelet count. Treatment approaches may include: […] Infection Management: Antibiotics or antiviral medications can help resolve infections, leading to a decrease in platelet counts.

• #10 High Platelet Count (Thrombocytosis): Symptoms, Causes and Treatment

  https://www.citizenshospitals.com/blogs/high-platelet-count-thrombocytosis-symptoms-causes-and-treatment

  Controlling Inflammation: Medications such as corticosteroids or disease-modifying anti-rheumatic drugs (DMARDs) may be prescribed to manage inflammatory conditions. […] Iron Supplementation: If iron deficiency is identified as the cause, iron supplements or dietary changes may be recommended to restore normal levels and reduce platelet counts. […] Monitoring: Regular follow-up appointments to monitor platelet counts and assess the effectiveness of treatment strategies.

• #11 Secondary Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560810/

  Thrombocytosis, or thrombocythemia, occurs when the platelet count exceeds 450,000/L of blood. […] Treatment focuses on addressing the underlying cause, which typically resolves the elevated platelet count. Antiplatelet therapy is generally unnecessary unless the platelet count is extremely high or there is a risk of thrombosis. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. […] Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #12 Secondary Thrombocytosis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/30100

  Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. For example, the normalization of platelet counts can be achieved by iron supplementation in inflammatory bowel patients. Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #13 Secondary Thrombocytosis Treatment & Management: Medical Care, Long-Term Monitoring

  https://emedicine.medscape.com/article/206811-treatment

  The primary treatment of secondary thrombocytosis (reactive thrombocytosis) should address the underlying cause of the thrombocytosis. For example, iron supplementation may normalize platelet counts in patients with thrombocytosis secondary to inflammatory bowel disease. […] In general, no treatment is indicated to directly reduce the platelet count. […] However, for patients with platelet counts in excess of 1,000,000/L, daily low-dose aspirin may be considered to minimize the rare development of stroke or thrombosis. […] A case report describes effective use of plateletpheresis for treatment of an internal carotid artery thrombus resulting in a right middle cerebral artery stroke, in a patient with previously undiagnosed reactive thrombocytosis (platelet count of 1,014,000/L) secondary to iron deficiency anemia. […] In patients with secondary thrombocytosis (reactive thrombocytosis) for whom the causal condition has not been identified, maintain careful outpatient monitoring with physical examination and routine laboratory tests to exclude the development of an occult disorder (eg, malignancy).

• #14 Secondary Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560810/

  Thrombocytosis, or thrombocythemia, occurs when the platelet count exceeds 450,000/L of blood. […] Treatment focuses on addressing the underlying cause, which typically resolves the elevated platelet count. Antiplatelet therapy is generally unnecessary unless the platelet count is extremely high or there is a risk of thrombosis. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. […] Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #15 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  On average, individuals with essential thrombocythemia (ET) have a normal life expectancy if they are properly monitored and treated. […] Prevention of blood clots (thrombosis) and bleeding (hemorrhaging) is the main objective of treating patients with ET. […] For patients with low-risk disease and no symptoms, the risk of complications may be low the doctor may prescribe low-dose aspirin or no therapy at all. On the other hand, for patients with high-risk disease, doctors may prescribe low-dose aspirin and other medications to reduce high platelet counts. […] Treatment of ET may include any or a combination of the following treatments listed below: […] Low-dose aspirin may reduce the risk of clotting complications. […] Cytoreductive therapy. This refers to a group of medications that reduce the number of blood cells in the bone marrow:

• #16 Essential thrombocythemia: Treatment and prognosis – UpToDate

  https://www.uptodate.com/contents/prognosis-and-treatment-of-essential-thrombocythemia

  Essential thrombocythemia (ET) is a BCR::ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive clonal platelet production. While at least one-half of patients with ET are asymptomatic at the time of diagnosis, most will develop vasomotor, thrombotic, or hemorrhagic manifestations at some point during their disease. A small percentage of patients will progress to post-ET myelofibrosis or experience leukemic transformation. Nevertheless, ET has the most favorable prognosis among the BCR::ABL1 MPNs. […] The goals of current management for patients with ET are to prevent thrombosis and bleeding and alleviate symptoms; current drug therapy has not been shown to prolong survival or prevent disease progression. […] TREATMENTS: Low-dose aspirin, Hydroxyurea, Pegylated interferon, Anagrelide, Alternative approaches.

• #17 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. […] Therefore, when it comes to treatment in ET or PV, less is more and one should avoid exposing patients to new drugs that have not been shown to be disease-modifying, and whose long-term consequences are suspect (e.g., ruxolitinib). […] Furthermore, the main indication for treatment in ET and PV is to prevent thrombosis and, in that regard, none of the newer drugs have been shown to be superior to the time-tested older drugs (e.g., hydroxyurea). […] Current indication for drug therapy in ET and PV is to prevent thrombotic complications, especially in high-risk patients. […] In the current review, we provide a risk-adapted treatment algorithm in ET that can be used in daily practice.

• #18 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Treatment for essential thrombocytosis (primary thrombocythemia) is aimed at preventing complications and alleviating symptoms; it does not necessarily prolong survival or slow disease progression. It should be individualized on the basis of risk factors for thrombosis or bleeding. Risk factors include the following: […] Lifestyle modifications should be recommended for all patients with reversible risk factors. These include diet and exercise to promote weight loss for obese patients and smoking cessation for smokers. […] The IPSET-thrombosis risk calculator may be used for risk stratification. It stratifies patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories. […] Observation may be appropriate for very-low-risk patients (ie, those lacking any of the above risk factors), although once-daily aspirin may be used in those with cardiovascular risk factors or symptoms.

• #19 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  At present, there is no evidence from prospective controlled studies to guide treatment recommendations for each one of the above-mentioned four risk categories in ET. […] Therefore, it is reasonable to consider further optimization of aspirin therapy in such patients by following twice-daily rather than once-daily schedule, especially in the presence of CV risk factors. […] Regardless, management of traditionally high-risk ET has been primarily guided by results of a randomized study of hydroxyurea vs no cytoreductive treatment, in high-risk patients, with the goal of keeping the platelet count below 60010(9)/L; the study showed a statistically significant benefit for hydroxyurea therapy (thrombosis rate of 3.6 vs 24%). […] Accordingly, hydroxyurea, combined with once-daily aspirin therapy, remains the standard of care for contemporarily classified high-risk patients.

• #20 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #21 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  Pankit Vachhani, MD: When I approach treatment for essential thrombocytosis, I keep in mind that there is no single drug or agent that that improves survival. My treatment goals are directed toward the mitigation of the thrombosis risk that these patients have. Also, there is no drug available that slows the progression of essential thrombocytosis to plastic-phase disease or overt myelofibrosis. My general approach to the treatment of essential thrombocytosis is thrombosis risk-adapted management, which largely follows the 4 risk categories found in the revised IPSET [International Prognostic Score for Thrombosis in Essential Thrombocythemia] stratification. […] For low-risk patients I suggest a daily aspirin but no cytoreductive therapy for very low-risk or low-risk patients. The caveat is that if patients present with a very high platelet count, lets say 1.5 million per mm3 or more or they have symptoms, I guide my treatment choice of cytoreductive therapy in those scenarios based on whether they meet certain indication for cytoreductive therapy.

• #22 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  At present, there is no evidence from prospective controlled studies to guide treatment recommendations for each one of the above-mentioned four risk categories in ET. […] Therefore, it is reasonable to consider further optimization of aspirin therapy in such patients by following twice-daily rather than once-daily schedule, especially in the presence of CV risk factors. […] Regardless, management of traditionally high-risk ET has been primarily guided by results of a randomized study of hydroxyurea vs no cytoreductive treatment, in high-risk patients, with the goal of keeping the platelet count below 60010(9)/L; the study showed a statistically significant benefit for hydroxyurea therapy (thrombosis rate of 3.6 vs 24%). […] Accordingly, hydroxyurea, combined with once-daily aspirin therapy, remains the standard of care for contemporarily classified high-risk patients.

• #23 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Treatment for essential thrombocytosis (primary thrombocythemia) is aimed at preventing complications and alleviating symptoms; it does not necessarily prolong survival or slow disease progression. It should be individualized on the basis of risk factors for thrombosis or bleeding. Risk factors include the following: […] Lifestyle modifications should be recommended for all patients with reversible risk factors. These include diet and exercise to promote weight loss for obese patients and smoking cessation for smokers. […] The IPSET-thrombosis risk calculator may be used for risk stratification. It stratifies patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories. […] Observation may be appropriate for very-low-risk patients (ie, those lacking any of the above risk factors), although once-daily aspirin may be used in those with cardiovascular risk factors or symptoms.

• #24 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Treatment for essential thrombocytosis (primary thrombocythemia) is aimed at preventing complications and alleviating symptoms; it does not necessarily prolong survival or slow disease progression. It should be individualized on the basis of risk factors for thrombosis or bleeding. Risk factors include the following: […] Lifestyle modifications should be recommended for all patients with reversible risk factors. These include diet and exercise to promote weight loss for obese patients and smoking cessation for smokers. […] The IPSET-thrombosis risk calculator may be used for risk stratification. It stratifies patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories. […] Observation may be appropriate for very-low-risk patients (ie, those lacking any of the above risk factors), although once-daily aspirin may be used in those with cardiovascular risk factors or symptoms.

• #25 Polycythemia Vera and Essential Thrombocythemia | AAFP

  https://www.aafp.org/pubs/afp/issues/2001/0215/p743.html

  In patients with polycythemia vera or essential thrombocythemia, vasomotor symptoms can be relieved with low-dose aspirin therapy (75 to 100 mg per day). However, use of aspirin should be avoided in patients with bleeding diathesis. The authors conclude that treatment of polycythemia vera or essential thrombocythemia should be directed by the presence of risk factors for thrombohemorrhagic complications.

• #26 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #27 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #28 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | mijn-bsl

  https://mijn.bsl.nl/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24011868

  Finally, a selective JAK1/JAK2 inhibitor, ruxolitinib, has been developed and has proven its efficacy in patients with both PCV and myelofibrosis, but its use in ET seems limited. […] In a large retrospective study of patients with primary thrombocytosis who received either antiplatelet agents, anticoagulation, cytoreductive treatment or underwent phlebotomy after a first thromboembolic complication, only cytoreductive therapy resulted in a significant reduction in recurrent ACS. […] Recently, the use of ASA twice daily has been advocated in specific individuals. […] An alternative way to prevent recurrent arterial events might be the use of more aggressive, e.g. double antiplatelet, therapy in the first 3-4 years following an arterial thrombotic event. […] Importantly, antiplatelet therapy plus anticoagulants should be used with caution, since their co-use was shown to result in an almost three times higher incidence of major bleeding as compared to either antiplatelet drugs or anticoagulants alone.

• #29 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #30 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  In those who have intermediate-risk essential thrombocytosis, I do aspirin and of course modification of cardiovascular risk factors. The use of cytoreductive therapy, typically hydroxyurea, is a decision that I base on other indications for the use of cytoreductive therapies. […] When it comes to high-risk essential thrombocytosis, using an aspirin and modifying cardiovascular risk factors are of course key, but cytoreductive therapy is definitely recommended in this group of patients. The first-line treatment that we use, especially in the United States, is hydroxyurea. […] For patients who are resistant or refractory to hydroxyurea use or, for example have an intolerance in the form of adverse events like ulcers or anemia, there are a few other options. One is anagrelide, which is a quinolone inhibitor that reduces the platelet count by inhibiting megakaryocytic differentiation.

• #31 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #32 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  Pankit Vachhani, MD: When I approach treatment for essential thrombocytosis, I keep in mind that there is no single drug or agent that that improves survival. My treatment goals are directed toward the mitigation of the thrombosis risk that these patients have. Also, there is no drug available that slows the progression of essential thrombocytosis to plastic-phase disease or overt myelofibrosis. My general approach to the treatment of essential thrombocytosis is thrombosis risk-adapted management, which largely follows the 4 risk categories found in the revised IPSET [International Prognostic Score for Thrombosis in Essential Thrombocythemia] stratification. […] For low-risk patients I suggest a daily aspirin but no cytoreductive therapy for very low-risk or low-risk patients. The caveat is that if patients present with a very high platelet count, lets say 1.5 million per mm3 or more or they have symptoms, I guide my treatment choice of cytoreductive therapy in those scenarios based on whether they meet certain indication for cytoreductive therapy.

• #33 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Your provider may recommend a few treatment options if you have essential thrombocythemia and are experiencing symptoms: […] Taking a daily low-dose aspirin: You can take a daily aspirin to prevent blood clots. The low dose doesnt usually cause stomach upset or bleeding. Be sure to check with your provider before taking aspirin regularly. […] Taking medicines that lower platelet levels: Medications such as hydroxyurea (Droxia, Hydrea, Siklos, Mylocel) and anagrelide (Agrilyn) suppress platelet production in your bone marrow. Interferon alfa (Multiferon) prevents abnormal platelets from dividing and multiplying. […] Having a procedure to remove your platelets: If your platelets are so high that theyre putting you at risk of life-threatening blood clots, your provider may recommend plateletpheresis. This procedure uses a machine to filter excess platelets from your blood. Most causes of thrombocytosis dont require plateletpheresis. […] Theres no cure for essential thrombocytosis, but your healthcare provider can help you manage the condition to reduce your risk of clots. High platelet levels associated with secondary causes usually return to normal once the underlying condition resolves.

• #34 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Plateletpheresis may be indicated as an emergency intervention, to achieve a rapid decrease in platelet counts in the setting of acute thrombosis and/or marked thrombocytosis. […] Cytoreductive therapy is used to reduce the risk of hemorrhage for patients with platelet counts above 1 million/L. […] Hydroxyurea is generally considered the first-line drug for cytoreductive therapy in essential thrombocytosis. […] A combination of cytoreductive agents may be needed in cases difficult to manage by single-agent therapy. […] A European study in 382 patients concluded that cytoreductive therapy should not be used in patients with essential thrombocytosis who are age 40 to 59 years and lack high-risk factors. […] Interferon alfa produces high rates of clinical and molecular responses in patients with JAK2 or CALR mutations.

• #35 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  This condition is considered less harmful today than in the past, and its outlook often is good. People who have no signs or symptoms don’t need treatment, as long as the condition remains stable. […] Taking aspirin may help people who are at risk for blood clots (aspirin thins the blood). However, talk with your doctor about using aspirin because it can cause bleeding. […] Some people who have primary thrombocythemia may need medicines or medical procedures to lower their platelet counts. […] You’ll need to take these medicines throughout your life. […] Hydroxyurea. This platelet-lowering medicine is used to treat cancers and other life-threatening diseases. Hydroxyurea most often is given under the care of doctors who specialize in cancer or blood diseases. Patients on hydroxyurea are closely monitored.

• #36 Tests and treatment for essential thrombocythaemia (ET) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/essential-thrombocythaemia/treatment

  Treatment for ET aims to reduce the number of platelets and lower the risk of blood clots. This helps to control your symptoms and to prevent any more serious problems. […] You might have one or more treatments. […] The main treatment is hydroxycarbamide, but you may have other treatments including: busulfan, anagrelide, peginterferon alfa-2a. […] Treatments for people with a high risk of developing blood clots include: low dose aspirin, hydroxycarbamide, anagrelide, busulfan, peginterferon alfa 2a. […] You take aspirin as a tablet. This can help to lower the number of platelets in the blood. This is also known as an anti platelet therapy. […] Hydroxycarbamide is a type of chemotherapy. This treatment uses cell killing (cytotoxic) drugs to destroy the extra platelets. […] Anagrelide is a medicine that is used to reduce the number of platelets. You take it as a capsule. […] Peginterferon alfa 2a is a type of immunotherapy. It stimulates cells of the immune system to attack the cancer. It can also help to control the number of platelets.

• #37 Polycythemia Vera and Essential Thrombocythemia | AAFP

  https://www.aafp.org/pubs/afp/issues/2001/0215/p743.html

  Polycythemia vera and essential thrombocythemia are chronic myeloproliferative diseases. The main goal of treatment in patients with these conditions is to prevent thrombo-hemorrhagic complications. […] When phlebotomy was the sole treatment of polycythemia vera, the average rate of survival was extended to more than 12 years. […] Based on this information, the authors recommend that all patients with polycythemia vera be treated with phlebotomy (with goal hematocrit levels of less than 45 percent [0.45] in men and 42 percent [0.42] in women); patients at high risk for thrombosis should also receive hydroxyurea. […] The risk of thrombosis is reduced by the use of hydroxyurea (from 24 percent to less than 4 percent) and by keeping the platelet count less than 400 103 per L (400 109 per L).

• #38 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | mijn-bsl

  https://mijn.bsl.nl/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24011868

  Generally, HU is the drug of first choice. […] In the landmark randomised clinical trial, HU was shown to reduce the risk of thrombotic complications from 10.7% to 1.6%. […] Due to concerns regarding an increased risk of development of leukaemia during the use of HU, other drugs such as anagrelide were developed. […] However, in subsequent trials HU+ASA were shown to be superior to anagrelide+ASA with regard to vascular events and transformation rates. […] For HU, there are no clear contraindications. […] Interferon is contraindicated in patients with known cardiovascular/thyroid disease. […] Anagrelide, a phosphodiesterase inhibitor with positive inotropic/chronotropic effects, should be used with caution in patients with known cardiovascular disease, and its use should be accompanied by accurate monitoring of cardiac function and QT interval before and during treatment.

• #39 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  Currently, hydroxyurea plus aspirin is the standard treatment for people who have primary thrombocythemia and are at high risk for blood clots. […] Anagrelide. This medicine also has been used to lower platelet counts in people who have thrombocythemia. However, research shows that when compared with hydroxyurea, anagrelide has worse outcomes. […] Interferon alfa. This medicine lowers platelet counts, but 20 percent of patients can’t handle its side effects. […] Doctors may prescribe this medicine to pregnant women who have primary thrombocythemia because it’s safer for a fetus than hydroxyurea and anagrelide. […] Plateletpheresis (PLATE-let-fe-REH-sis) is a procedure used to rapidly lower your platelet count. This procedure is used only for emergencies. […] One or two procedures might be enough to reduce your platelet count to a safe level. […] Secondary thrombocytosis is treated by addressing the condition that’s causing it. […] People who have secondary thrombocytosis usually don’t need platelet-lowering medicines or procedures.

• #40 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  This condition is considered less harmful today than in the past, and its outlook often is good. People who have no signs or symptoms don’t need treatment, as long as the condition remains stable. […] Taking aspirin may help people who are at risk for blood clots (aspirin thins the blood). However, talk with your doctor about using aspirin because it can cause bleeding. […] Some people who have primary thrombocythemia may need medicines or medical procedures to lower their platelet counts. […] You’ll need to take these medicines throughout your life. […] Hydroxyurea. This platelet-lowering medicine is used to treat cancers and other life-threatening diseases. Hydroxyurea most often is given under the care of doctors who specialize in cancer or blood diseases. Patients on hydroxyurea are closely monitored.

• #41 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Your provider may recommend a few treatment options if you have essential thrombocythemia and are experiencing symptoms: […] Taking a daily low-dose aspirin: You can take a daily aspirin to prevent blood clots. The low dose doesnt usually cause stomach upset or bleeding. Be sure to check with your provider before taking aspirin regularly. […] Taking medicines that lower platelet levels: Medications such as hydroxyurea (Droxia, Hydrea, Siklos, Mylocel) and anagrelide (Agrilyn) suppress platelet production in your bone marrow. Interferon alfa (Multiferon) prevents abnormal platelets from dividing and multiplying. […] Having a procedure to remove your platelets: If your platelets are so high that theyre putting you at risk of life-threatening blood clots, your provider may recommend plateletpheresis. This procedure uses a machine to filter excess platelets from your blood. Most causes of thrombocytosis dont require plateletpheresis. […] Theres no cure for essential thrombocytosis, but your healthcare provider can help you manage the condition to reduce your risk of clots. High platelet levels associated with secondary causes usually return to normal once the underlying condition resolves.

• #42 Treatments for High Platelet Count (Thrombocythemia)

  https://www.trialsearch.com/blood-conditions/blood-clots/thrombocythemia-high-platelet-count/treatment

  Anagrelide (Agrylin) is a platelet-reducing agent prescribed for treating thrombocythemia and other MPNs. This medication stops megakaryocytes from maturing, preventing them from making platelets. As a result, your platelet levels gradually decrease to normal levels. […] Interferon alfa (Intron A, Roferon-A) is an antiviral drug typically used to treat hepatitis (liver inflammation) caused by viral infections, in addition to certain types of cancer. It also blocks the growth of immature megakaryocytes to help reduce platelet count in people with thrombocythemia. […] Thrombocythemia can also be treated with plateletpheresis. Also known as platelet reduction apheresis, this procedure removes extra platelets from your blood and returns your filtered blood to you.

• #43 Essential thrombocytosis: diagnosis, differential diagnosis, complications and treatment considerations of relevance for a cardiologist | mijn-bsl

  https://mijn.bsl.nl/essential-thrombocytosis-diagnosis-differential-diagnosis-compli/24011868

  Generally, HU is the drug of first choice. […] In the landmark randomised clinical trial, HU was shown to reduce the risk of thrombotic complications from 10.7% to 1.6%. […] Due to concerns regarding an increased risk of development of leukaemia during the use of HU, other drugs such as anagrelide were developed. […] However, in subsequent trials HU+ASA were shown to be superior to anagrelide+ASA with regard to vascular events and transformation rates. […] For HU, there are no clear contraindications. […] Interferon is contraindicated in patients with known cardiovascular/thyroid disease. […] Anagrelide, a phosphodiesterase inhibitor with positive inotropic/chronotropic effects, should be used with caution in patients with known cardiovascular disease, and its use should be accompanied by accurate monitoring of cardiac function and QT interval before and during treatment.

• #44 Essential thrombocythemia (ET) – MPN Research Foundation

  https://mpnresearchfoundation.org/essential-thrombocythemia-et/

  When treatment is necessary, the available treatment options for ET patients include: […] Low-dose aspirin is usually given to reduce the risk of blood clotting. Aspirin may also help relieve the burning sensation that some ET patients experience in their hands and feet (erythromelalgia, along with other vasomotor symptoms). […] Hydroxyurea is often used to treat ET patients at high risk for clotting (over 60 years-old or patients with a prior blood clot). It is usually considered the first line agent for patients that require treatment. […] Anagrelide is another option for lowering platelet counts. It is frequently used after a patient has demonstrated intolerance or experienced complications with Hydroxyurea. […] Interferon (typically pegylated) is sometimes prescribed for ET patients. Women of childbearing age are often treated with interferon because it hasnt been shown to cause birth defects.

• #45 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  In those who have intermediate-risk essential thrombocytosis, I do aspirin and of course modification of cardiovascular risk factors. The use of cytoreductive therapy, typically hydroxyurea, is a decision that I base on other indications for the use of cytoreductive therapies. […] When it comes to high-risk essential thrombocytosis, using an aspirin and modifying cardiovascular risk factors are of course key, but cytoreductive therapy is definitely recommended in this group of patients. The first-line treatment that we use, especially in the United States, is hydroxyurea. […] For patients who are resistant or refractory to hydroxyurea use or, for example have an intolerance in the form of adverse events like ulcers or anemia, there are a few other options. One is anagrelide, which is a quinolone inhibitor that reduces the platelet count by inhibiting megakaryocytic differentiation.

• #46 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  Currently, hydroxyurea plus aspirin is the standard treatment for people who have primary thrombocythemia and are at high risk for blood clots. […] Anagrelide. This medicine also has been used to lower platelet counts in people who have thrombocythemia. However, research shows that when compared with hydroxyurea, anagrelide has worse outcomes. […] Interferon alfa. This medicine lowers platelet counts, but 20 percent of patients can’t handle its side effects. […] Doctors may prescribe this medicine to pregnant women who have primary thrombocythemia because it’s safer for a fetus than hydroxyurea and anagrelide. […] Plateletpheresis (PLATE-let-fe-REH-sis) is a procedure used to rapidly lower your platelet count. This procedure is used only for emergencies. […] One or two procedures might be enough to reduce your platelet count to a safe level. […] Secondary thrombocytosis is treated by addressing the condition that’s causing it. […] People who have secondary thrombocytosis usually don’t need platelet-lowering medicines or procedures.

• #47 Platelet Disorders – Thrombocythemia and Thrombocytosis | NHLBI, NIH

  https://www.nhlbi.nih.gov/health/thrombocythemia-thrombocytosis

  People who have thrombocythemia with no symptoms often do not need treatment. Other people who have this condition may need medicines or procedures to treat it. Treatment does not cure your condition, but it can help prevent blood clots and serious complications. […] Treatment for secondary thrombocytosis depends on its cause. People who have thrombocytosis usually do not need platelet-lowering medicines or procedures. This is because their platelets are usually normal and less likely to cause serious blood clots or bleeding. […] Treatment for thrombocythemia may include medicines and procedures. […] You may need one of the following medicines to lower your platelet count. […] Anagrelide: This medicine is used to lower platelet counts. It is mostly used when hydroxyurea does not work. Anagrelide also has side effects, such as fluid retention, palpitations, arrhythmias, heart failure, and headaches.

• #48 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Your provider may recommend a few treatment options if you have essential thrombocythemia and are experiencing symptoms: […] Taking a daily low-dose aspirin: You can take a daily aspirin to prevent blood clots. The low dose doesnt usually cause stomach upset or bleeding. Be sure to check with your provider before taking aspirin regularly. […] Taking medicines that lower platelet levels: Medications such as hydroxyurea (Droxia, Hydrea, Siklos, Mylocel) and anagrelide (Agrilyn) suppress platelet production in your bone marrow. Interferon alfa (Multiferon) prevents abnormal platelets from dividing and multiplying. […] Having a procedure to remove your platelets: If your platelets are so high that theyre putting you at risk of life-threatening blood clots, your provider may recommend plateletpheresis. This procedure uses a machine to filter excess platelets from your blood. Most causes of thrombocytosis dont require plateletpheresis. […] Theres no cure for essential thrombocytosis, but your healthcare provider can help you manage the condition to reduce your risk of clots. High platelet levels associated with secondary causes usually return to normal once the underlying condition resolves.

• #49 Take a look at the Recent articles

  https://www.oatext.com/Immunotherapy-and-essential-thrombocythemia.php

  The past few decades have witnessed significant advances in the understanding of the etiology, diagnosis and treatment of essential thrombocythemia (ET), but more detailed insights are required to understand the pathophysiologic mechanism of the disease in ET patients. […] However, to achieve better patient outcomes such as improved quality of life and for effective therapeutic decisions, possibilities of combining different immunotherapies should be explored. […] Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to MPNs, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms, including thrombo-hemorrhagic events. […] IFN suppresses the proliferation of hematopoietic progenitors, has a direct inhibiting effect on bone marrow fibroblast progenitor cells, and antagonizes the action of platelet-derived growth factor, transforming growth factor- and other cytokines that may be involved in the development of myelofibrosis.

• #50 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  Currently, hydroxyurea plus aspirin is the standard treatment for people who have primary thrombocythemia and are at high risk for blood clots. […] Anagrelide. This medicine also has been used to lower platelet counts in people who have thrombocythemia. However, research shows that when compared with hydroxyurea, anagrelide has worse outcomes. […] Interferon alfa. This medicine lowers platelet counts, but 20 percent of patients can’t handle its side effects. […] Doctors may prescribe this medicine to pregnant women who have primary thrombocythemia because it’s safer for a fetus than hydroxyurea and anagrelide. […] Plateletpheresis (PLATE-let-fe-REH-sis) is a procedure used to rapidly lower your platelet count. This procedure is used only for emergencies. […] One or two procedures might be enough to reduce your platelet count to a safe level. […] Secondary thrombocytosis is treated by addressing the condition that’s causing it. […] People who have secondary thrombocytosis usually don’t need platelet-lowering medicines or procedures.

• #51 Essential thrombocythemia (ET) – MPN Research Foundation

  https://mpnresearchfoundation.org/essential-thrombocythemia-et/

  When treatment is necessary, the available treatment options for ET patients include: […] Low-dose aspirin is usually given to reduce the risk of blood clotting. Aspirin may also help relieve the burning sensation that some ET patients experience in their hands and feet (erythromelalgia, along with other vasomotor symptoms). […] Hydroxyurea is often used to treat ET patients at high risk for clotting (over 60 years-old or patients with a prior blood clot). It is usually considered the first line agent for patients that require treatment. […] Anagrelide is another option for lowering platelet counts. It is frequently used after a patient has demonstrated intolerance or experienced complications with Hydroxyurea. […] Interferon (typically pegylated) is sometimes prescribed for ET patients. Women of childbearing age are often treated with interferon because it hasnt been shown to cause birth defects.

• #52 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  There are currently four drugs to consider as second-line therapy in ET: pegylated interferon- (IFN-), busulfan, anagrelide, and pipobroman. […] Current treatment recommendations in young women wishing to be pregnant or are pregnant include once-daily aspirin for very low-risk or low-risk disease and pegylated IFN- for high-risk disease. […] Cytoreductive treatment is strongly encouraged in patients with thrombosis history, and our first- and second-line drugs of choice in this regard are hydroxyurea and pegylated IFN-, respectively.

• #53 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  Currently, hydroxyurea plus aspirin is the standard treatment for people who have primary thrombocythemia and are at high risk for blood clots. […] Anagrelide. This medicine also has been used to lower platelet counts in people who have thrombocythemia. However, research shows that when compared with hydroxyurea, anagrelide has worse outcomes. […] Interferon alfa. This medicine lowers platelet counts, but 20 percent of patients can’t handle its side effects. […] Doctors may prescribe this medicine to pregnant women who have primary thrombocythemia because it’s safer for a fetus than hydroxyurea and anagrelide. […] Plateletpheresis (PLATE-let-fe-REH-sis) is a procedure used to rapidly lower your platelet count. This procedure is used only for emergencies. […] One or two procedures might be enough to reduce your platelet count to a safe level. […] Secondary thrombocytosis is treated by addressing the condition that’s causing it. […] People who have secondary thrombocytosis usually don’t need platelet-lowering medicines or procedures.

• #54 Platelet Disorders – Thrombocythemia and Thrombocytosis | NHLBI, NIH

  https://www.nhlbi.nih.gov/health/thrombocythemia-thrombocytosis

  Aspirin: This medicine helps prevent blood clots. It is mostly used in people who have a low risk of blood clots. If you have a high risk of blood clots, you may need to take both aspirin and hydroxyurea. […] Hydroxyurea: This platelet-lowering medicine is used to treat cancers and sickle cell disease, for example. […] Interferon alfa: This medicine lowers platelet counts, but it can have serious side effects. Side effects may include a flu-like feeling, decreased appetite, nausea (feeling sick to the stomach), diarrhea, seizures, irritability, and sleepiness. […] Plateletpheresis is a procedure used to quickly lower your platelet count. This procedure is mostly used for emergencies. For example, if you are having a stroke due to primary thrombocythemia, you may need plateletpheresis.

• #55 Management and Treatment of Essential Thrombocythemia

  https://www.targetedonc.com/view/management-and-treatment-of-essential-thrombocythemia

  We were really excited that we had a novel interferon called ropeginterferon interferon approved in patients with PV back in 2021. That has been preceded by approval in the European Union before, in 2019. That’s an excellent option in terms of interferon, subcutaneous items. Patients will have to inject themselves and the pegylated is once a week. The standard recombinant is more than weekly, so the novel alternative way, the ropeginterferon which is the novel monoregulated form, is kind of more convenient because it’s used every other week. Once we reach complete hematologic control, it’s used once a month. So that’s a significant improvement in convenience for patients and tolerability, as well as compliance issues. We were excited to get it in PV. We have it in some studies in PV to expand the access and maybe try some different schedules, and will also move it to patients [with ET]. That’s something that we’re going to be looking at.

• #56 Platelet Disorders – Thrombocythemia and Thrombocytosis | NHLBI, NIH

  https://www.nhlbi.nih.gov/health/thrombocythemia-thrombocytosis

  Aspirin: This medicine helps prevent blood clots. It is mostly used in people who have a low risk of blood clots. If you have a high risk of blood clots, you may need to take both aspirin and hydroxyurea. […] Hydroxyurea: This platelet-lowering medicine is used to treat cancers and sickle cell disease, for example. […] Interferon alfa: This medicine lowers platelet counts, but it can have serious side effects. Side effects may include a flu-like feeling, decreased appetite, nausea (feeling sick to the stomach), diarrhea, seizures, irritability, and sleepiness. […] Plateletpheresis is a procedure used to quickly lower your platelet count. This procedure is mostly used for emergencies. For example, if you are having a stroke due to primary thrombocythemia, you may need plateletpheresis.

• #57 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  This condition is considered less harmful today than in the past, and its outlook often is good. People who have no signs or symptoms don’t need treatment, as long as the condition remains stable. […] Taking aspirin may help people who are at risk for blood clots (aspirin thins the blood). However, talk with your doctor about using aspirin because it can cause bleeding. […] Some people who have primary thrombocythemia may need medicines or medical procedures to lower their platelet counts. […] You’ll need to take these medicines throughout your life. […] Hydroxyurea. This platelet-lowering medicine is used to treat cancers and other life-threatening diseases. Hydroxyurea most often is given under the care of doctors who specialize in cancer or blood diseases. Patients on hydroxyurea are closely monitored.

• #58 Treatments for High Platelet Count (Thrombocythemia)

  https://www.trialsearch.com/blood-conditions/blood-clots/thrombocythemia-high-platelet-count/treatment

  Thrombocythemia treatments focus on reducing cells in the bone marrow to limit platelet production, in addition to thinning the blood to prevent blood clots. You may, in emergent situations, also undergo treatment to filter out extra platelets from your blood. […] Treatments are typically used only for more severe cases in those who have symptoms from blood clots. Unfortunately, there are no cures for thrombocythemia, but currently available therapies make it possible to live a long, healthy life. […] Hydroxyurea helps reduce the number of cells in the bone marrow, such as megakaryocytes. As a result, your bone marrow produces fewer platelets, lowering your counts to prevent blood clots. Hydroxyurea is available as a tablet or capsule thats taken once daily with water. […] Aspirin is a well-known preventative treatment for blood clots and heart attacks. Doctors prescribe Aspirin to thrombocythemia patients due to its blood-thinning effects. Specifically, it stops platelets from sticking together, preventing blood clots from forming.

• #59 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  On average, individuals with essential thrombocythemia (ET) have a normal life expectancy if they are properly monitored and treated. […] Prevention of blood clots (thrombosis) and bleeding (hemorrhaging) is the main objective of treating patients with ET. […] For patients with low-risk disease and no symptoms, the risk of complications may be low the doctor may prescribe low-dose aspirin or no therapy at all. On the other hand, for patients with high-risk disease, doctors may prescribe low-dose aspirin and other medications to reduce high platelet counts. […] Treatment of ET may include any or a combination of the following treatments listed below: […] Low-dose aspirin may reduce the risk of clotting complications. […] Cytoreductive therapy. This refers to a group of medications that reduce the number of blood cells in the bone marrow:

• #60 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  At present, there is no evidence from prospective controlled studies to guide treatment recommendations for each one of the above-mentioned four risk categories in ET. […] Therefore, it is reasonable to consider further optimization of aspirin therapy in such patients by following twice-daily rather than once-daily schedule, especially in the presence of CV risk factors. […] Regardless, management of traditionally high-risk ET has been primarily guided by results of a randomized study of hydroxyurea vs no cytoreductive treatment, in high-risk patients, with the goal of keeping the platelet count below 60010(9)/L; the study showed a statistically significant benefit for hydroxyurea therapy (thrombosis rate of 3.6 vs 24%). […] Accordingly, hydroxyurea, combined with once-daily aspirin therapy, remains the standard of care for contemporarily classified high-risk patients.

• #61 Essential Thrombocythemia – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/essential-thrombocythemia

  Sometimes aspirin […] Platelet-lowering medications (eg, pegylated interferon, anagrelide) […] Rarely plateletpheresis […] Rarely cytotoxic agents such as hydroxyurea […] Rarely stem cell transplantation. Aspirin 81 mg orally once a day is usually sufficient for mild vasomotor symptoms (eg, headache, mild digital ischemia, erythromelalgia) in low-risk patients (without cardiovascular disease) who do not have the JAK2 mutation, but a higher dose may be used if necessary. JAK2 inhibitors such as ruxolitinib may be effective for the treatment of essential thrombocythemia. Drugs used to lower platelet count include anagrelide, interferon alfa-2b, and hydroxyurea. Hydroxyurea should be prescribed only by specialists familiar with its use and monitoring and never for long-term use. Because anagrelide and hydroxyurea cross the placenta, they are not used during pregnancy; pegylated interferon alfa-2a can be used in pregnant women when necessary. Ruxolitinib, added to the best available therapy, may be effective in essential thrombocythemia

• #62 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  Treatment for this condition depends on the cause. […] If you’ve had significant blood loss from a recent surgery or an injury, your elevated platelet count might resolve on its own. […] If you have a chronic infection or an inflammatory disease, your platelet count likely will remain high until the condition is under control. In most cases, your platelet count will return to normal after the cause is resolved. […] If you’ve had your spleen removed, you might have lifelong thrombocytosis, but you’re unlikely to need treatment. […] People with this condition who have no signs or symptoms usually don’t need treatment. You might need to take daily, low-dose aspirin to help thin your blood if you’re at risk of blood clots. Don’t take aspirin without checking with your health care team.

• #63 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  This condition is considered less harmful today than in the past, and its outlook often is good. People who have no signs or symptoms don’t need treatment, as long as the condition remains stable. […] Taking aspirin may help people who are at risk for blood clots (aspirin thins the blood). However, talk with your doctor about using aspirin because it can cause bleeding. […] Some people who have primary thrombocythemia may need medicines or medical procedures to lower their platelet counts. […] You’ll need to take these medicines throughout your life. […] Hydroxyurea. This platelet-lowering medicine is used to treat cancers and other life-threatening diseases. Hydroxyurea most often is given under the care of doctors who specialize in cancer or blood diseases. Patients on hydroxyurea are closely monitored.

• #64 An Update on Current and Emergent Therapies for Essential Thrombocytosis

  https://www.targetedonc.com/view/an-update-on-current-and-emergent-therapies-for-essential-thrombocytosis

  Hydroxyurea (HU) and pegylated interferon alfa (peg-IFN) are the primary options for frontline cytoreductive treatment. […] In cases where initial treatment approaches do not yield satisfactory results, anagrelide is another option, though its use is often limited by toxicities (eg, headaches, dizziness, palpitations, and fluid retention). […] As we delve deeper into understanding the biologic drivers of ET, promising new therapeutic directions are emerging, including JAK inhibitors, epigenetic agents, and mutation-specific biologic/immunologic therapies. […] Ruxolitinib (Jakafi), a JAK1/2 inhibitor already widely used for other MPNs, continues to be evaluated in ET. […] Another ongoing trial called Ruxo-BEAT [NCT02577926] is further exploring the use of ruxolitinib in ET. […] The BET inhibitor pelabresib (CPI-0610) is currently being evaluated for ET as well as myelofibrosis.

• #65 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  However, interferon alfa-2b was discontinued in 2021. […] Ruxolitinib is a JAK1/JAK2 inhibitor that is approved for use in myelofibrosis and polycythemia vera, and some benefit has been reported in patients with essential thrombocytosis. […] Another JAK inhibitor, fedratinib, is indicated for adults with intermediate-2 or high-risk postessential thrombocythemia myelofibrosis. […] The investigational drug imetelstat, a telomerase inhibitor, has shown promise in the treatment of essential thrombocytosis. […] Patients with essential thrombocytosis who undergo surgery are at increased risk for bleeding and thrombosis. When indicated, administer cytoreductive therapy to decrease the platelet count to the reference range before surgery.

• #66 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  We typically restrict the use of anagrelide in the second-line setting. Another agent of note is interferon. Interferon has been looked into in essential thrombocytosis for many years. […] We typically restrict interferon to the relapsed/refractory or intolerant setting for essential thrombocytosis. […] Options beyond interferon and anagrelide include drugs that may have genome toxicity that and we rarely use. But also ruxolitinib has been studied in the MAGIC trial. Unfortunately, the MAGIC trial did not show any major difference between Hydrea and ruxolitinib. However, those who had symptoms found more resolution of symptoms with ruxolitinib rather than hydroxyurea.

• #67 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  However, interferon alfa-2b was discontinued in 2021. […] Ruxolitinib is a JAK1/JAK2 inhibitor that is approved for use in myelofibrosis and polycythemia vera, and some benefit has been reported in patients with essential thrombocytosis. […] Another JAK inhibitor, fedratinib, is indicated for adults with intermediate-2 or high-risk postessential thrombocythemia myelofibrosis. […] The investigational drug imetelstat, a telomerase inhibitor, has shown promise in the treatment of essential thrombocytosis. […] Patients with essential thrombocytosis who undergo surgery are at increased risk for bleeding and thrombosis. When indicated, administer cytoreductive therapy to decrease the platelet count to the reference range before surgery.

• #68 An Update on Current and Emergent Therapies for Essential Thrombocytosis

  https://www.targetedonc.com/view/an-update-on-current-and-emergent-therapies-for-essential-thrombocytosis

  Hydroxyurea (HU) and pegylated interferon alfa (peg-IFN) are the primary options for frontline cytoreductive treatment. […] In cases where initial treatment approaches do not yield satisfactory results, anagrelide is another option, though its use is often limited by toxicities (eg, headaches, dizziness, palpitations, and fluid retention). […] As we delve deeper into understanding the biologic drivers of ET, promising new therapeutic directions are emerging, including JAK inhibitors, epigenetic agents, and mutation-specific biologic/immunologic therapies. […] Ruxolitinib (Jakafi), a JAK1/2 inhibitor already widely used for other MPNs, continues to be evaluated in ET. […] Another ongoing trial called Ruxo-BEAT [NCT02577926] is further exploring the use of ruxolitinib in ET. […] The BET inhibitor pelabresib (CPI-0610) is currently being evaluated for ET as well as myelofibrosis.

• #69 An Update on Current and Emergent Therapies for Essential Thrombocytosis

  https://www.targetedonc.com/view/an-update-on-current-and-emergent-therapies-for-essential-thrombocytosis

  The LSD1 inhibitor bomedemstat is also being studied for both ET and MF, and preliminary reports from the ET study show encouraging ability to control platelets and improve symptoms for many patients. […] Recently, at the American Society of Hematology annual meeting in 2022, preclinical data were presented on a monoclonal antibody that targets mutant CALR, a key diver for approximately 25% of patients with ET. […] The development of more targeted agents with the potential to meaningfully disrupt the mechanisms driving MPNs provides a lot of optimism for the future in these diseases.

• #70 Essential thrombocythemia – Wikipedia

  https://en.wikipedia.org/wiki/Essential_thrombocythemia

  Treatment Low-dose aspirin, plateletpheresis, cytoreductive therapy.[1] […] Patients are usually designated as having a low or high risk of bleeding or developing blood clots based on their age, medical history, blood counts and their lifestyles. Low risk individuals are usually treated with aspirin, whereas those at high risk are treated with hydroxycarbamide, interferon- or anagrelide.[3][15][16][17] Currently unapproved but in late-stage clinical trials (NCT04254978) are agents that lower platelets such as bomedemstat. […] Hydroxycarbamide, interferon- and anagrelide can lower the platelet count. Low-dose aspirin is used to reduce the risk of blood clot formation unless the platelet count is very high, where there is a risk of bleeding from the disease, and hence this measure would be counter-productive as aspirin-use increases the risk of bleeding.[3][15][16][17] […] In people with symptomatic ET and extremely high platelet counts (exceeding 1 million), plateletpheresis can be used to remove platelets from the blood to reduce the risk of thrombosis.[18]

• #71 An Update on Current and Emergent Therapies for Essential Thrombocytosis

  https://www.targetedonc.com/view/an-update-on-current-and-emergent-therapies-for-essential-thrombocytosis

  The LSD1 inhibitor bomedemstat is also being studied for both ET and MF, and preliminary reports from the ET study show encouraging ability to control platelets and improve symptoms for many patients. […] Recently, at the American Society of Hematology annual meeting in 2022, preclinical data were presented on a monoclonal antibody that targets mutant CALR, a key diver for approximately 25% of patients with ET. […] The development of more targeted agents with the potential to meaningfully disrupt the mechanisms driving MPNs provides a lot of optimism for the future in these diseases.

• #72 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Your provider may recommend a few treatment options if you have essential thrombocythemia and are experiencing symptoms: […] Taking a daily low-dose aspirin: You can take a daily aspirin to prevent blood clots. The low dose doesnt usually cause stomach upset or bleeding. Be sure to check with your provider before taking aspirin regularly. […] Taking medicines that lower platelet levels: Medications such as hydroxyurea (Droxia, Hydrea, Siklos, Mylocel) and anagrelide (Agrilyn) suppress platelet production in your bone marrow. Interferon alfa (Multiferon) prevents abnormal platelets from dividing and multiplying. […] Having a procedure to remove your platelets: If your platelets are so high that theyre putting you at risk of life-threatening blood clots, your provider may recommend plateletpheresis. This procedure uses a machine to filter excess platelets from your blood. Most causes of thrombocytosis dont require plateletpheresis. […] Theres no cure for essential thrombocytosis, but your healthcare provider can help you manage the condition to reduce your risk of clots. High platelet levels associated with secondary causes usually return to normal once the underlying condition resolves.

• #73 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Plateletpheresis may be indicated as an emergency intervention, to achieve a rapid decrease in platelet counts in the setting of acute thrombosis and/or marked thrombocytosis. […] Cytoreductive therapy is used to reduce the risk of hemorrhage for patients with platelet counts above 1 million/L. […] Hydroxyurea is generally considered the first-line drug for cytoreductive therapy in essential thrombocytosis. […] A combination of cytoreductive agents may be needed in cases difficult to manage by single-agent therapy. […] A European study in 382 patients concluded that cytoreductive therapy should not be used in patients with essential thrombocytosis who are age 40 to 59 years and lack high-risk factors. […] Interferon alfa produces high rates of clinical and molecular responses in patients with JAK2 or CALR mutations.

• #74 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  This is a process that uses a special machine to skim platelets from a patients blood and then return the remaining blood components to the patient. […] Taking part in a clinical trial may be the best treatment choice for some ET patients. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers.

• #75 Treatments for High Platelet Count (Thrombocythemia)

  https://www.trialsearch.com/blood-conditions/blood-clots/thrombocythemia-high-platelet-count/treatment

  Anagrelide (Agrylin) is a platelet-reducing agent prescribed for treating thrombocythemia and other MPNs. This medication stops megakaryocytes from maturing, preventing them from making platelets. As a result, your platelet levels gradually decrease to normal levels. […] Interferon alfa (Intron A, Roferon-A) is an antiviral drug typically used to treat hepatitis (liver inflammation) caused by viral infections, in addition to certain types of cancer. It also blocks the growth of immature megakaryocytes to help reduce platelet count in people with thrombocythemia. […] Thrombocythemia can also be treated with plateletpheresis. Also known as platelet reduction apheresis, this procedure removes extra platelets from your blood and returns your filtered blood to you.

• #76 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  You might need to take prescription medicine or have procedures to lower your platelet counts if you: Have a history of blood clots and bleeding. […] Your doctor might prescribe platelet-lowering drugs such as hydroxyurea (Droxia, Hydrea), anagrelide (Agrylin) or interferon alfa (Intron A). […] In emergencies, platelets can be filtered from your blood with a machine. This procedure is called plateletpheresis. The effects are only temporary.

• #77 Thrombocytosis in the ED – emDocs

  https://www.emdocs.net/thrombocytosis-in-the-ed/

  Treatment includes: Anticoagulation with low molecular weight heparin. NOAC’s should be avoided due to lack of data in myeloproliferative neoplasms and potential for drug interactions with JAK inhibitors. Cytoreductive agent (see table below), with platelet goal <400,000/microL. ASA 81mg daily. Immediate platelet apheresis if platelets >800,000/microL. […] Given the relatively high incidence of thrombotic complications in essential thrombocythemia, high-risk, asymptomatic patients should be treated prophylactically with antiplatelet agents + cytoreductive agents. Essential thrombocythemia patients with acute thrombotic complications require treatment with a cytoreductive agent, anticoagulation, aspirin, and possibly apheresis.

• #78 Thrombocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/diagnosis-treatment/drc-20378319

  You might need to take prescription medicine or have procedures to lower your platelet counts if you: Have a history of blood clots and bleeding. […] Your doctor might prescribe platelet-lowering drugs such as hydroxyurea (Droxia, Hydrea), anagrelide (Agrylin) or interferon alfa (Intron A). […] In emergencies, platelets can be filtered from your blood with a machine. This procedure is called plateletpheresis. The effects are only temporary.

• #79 Essential Thrombocythemia – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/essential-thrombocythemia

  Platelet removal (plateletpheresis) has been used in rare patients with serious hemorrhage or recurrent thrombosis or before emergency surgery to immediately reduce the platelet count. However, plateletpheresis is rarely necessary. Its effects are transient with prompt rebound in the platelet count. Hydroxyurea or anagrelide do not provide an immediate effect but should be started at the same time as plateletpheresis.

• #80 Living with Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/living-thrombocythemia-and

  See your doctor for ongoing medical care. […] If you’re taking medicines to lower your platelet count, tell your doctor or dentist about them before any surgical or dental procedures. These medicines thin your blood and may increase bleeding during these procedures. […] Medicines that thin the blood also may cause internal bleeding. […] Contact your doctor right away if you have any of these signs. […] Avoid over-the-counter pain medicines such as ibuprofen (except Tylenol). These medicines may raise your risk of bleeding in the stomach or intestines and may limit the effect of aspirin.

• #81 Secondary Thrombocytosis Treatment & Management: Medical Care, Long-Term Monitoring

  https://emedicine.medscape.com/article/206811-treatment

  The primary treatment of secondary thrombocytosis (reactive thrombocytosis) should address the underlying cause of the thrombocytosis. For example, iron supplementation may normalize platelet counts in patients with thrombocytosis secondary to inflammatory bowel disease. […] In general, no treatment is indicated to directly reduce the platelet count. […] However, for patients with platelet counts in excess of 1,000,000/L, daily low-dose aspirin may be considered to minimize the rare development of stroke or thrombosis. […] A case report describes effective use of plateletpheresis for treatment of an internal carotid artery thrombus resulting in a right middle cerebral artery stroke, in a patient with previously undiagnosed reactive thrombocytosis (platelet count of 1,014,000/L) secondary to iron deficiency anemia. […] In patients with secondary thrombocytosis (reactive thrombocytosis) for whom the causal condition has not been identified, maintain careful outpatient monitoring with physical examination and routine laboratory tests to exclude the development of an occult disorder (eg, malignancy).

• #82 Living with Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/living-thrombocythemia-and

  See your doctor for ongoing medical care. […] If you’re taking medicines to lower your platelet count, tell your doctor or dentist about them before any surgical or dental procedures. These medicines thin your blood and may increase bleeding during these procedures. […] Medicines that thin the blood also may cause internal bleeding. […] Contact your doctor right away if you have any of these signs. […] Avoid over-the-counter pain medicines such as ibuprofen (except Tylenol). These medicines may raise your risk of bleeding in the stomach or intestines and may limit the effect of aspirin.

• #83 Living with Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/living-thrombocythemia-and

  See your doctor for ongoing medical care. […] If you’re taking medicines to lower your platelet count, tell your doctor or dentist about them before any surgical or dental procedures. These medicines thin your blood and may increase bleeding during these procedures. […] Medicines that thin the blood also may cause internal bleeding. […] Contact your doctor right away if you have any of these signs. […] Avoid over-the-counter pain medicines such as ibuprofen (except Tylenol). These medicines may raise your risk of bleeding in the stomach or intestines and may limit the effect of aspirin.

• #84 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  However, interferon alfa-2b was discontinued in 2021. […] Ruxolitinib is a JAK1/JAK2 inhibitor that is approved for use in myelofibrosis and polycythemia vera, and some benefit has been reported in patients with essential thrombocytosis. […] Another JAK inhibitor, fedratinib, is indicated for adults with intermediate-2 or high-risk postessential thrombocythemia myelofibrosis. […] The investigational drug imetelstat, a telomerase inhibitor, has shown promise in the treatment of essential thrombocytosis. […] Patients with essential thrombocytosis who undergo surgery are at increased risk for bleeding and thrombosis. When indicated, administer cytoreductive therapy to decrease the platelet count to the reference range before surgery.

• #85 Thrombocytosis – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/thrombocytosis/symptoms-causes/syc-20378315

  It’s important to determine whether it’s reactive thrombocytosis or essential thrombocythemia to choose the best treatment options. […] The cause of this disorder is unclear. It often appears to be connected to changes in certain genes. The bone marrow produces too many of the cells that form platelets, and these platelets often don’t work properly. This poses a much higher risk of clotting or bleeding complications than does reactive thrombocytosis. […] Your risk of pregnancy complications may be reduced with regular checkups and medication, so be sure to have your doctor regularly monitor your condition. […] Tefferi A. Prognosis and treatment of essential thrombocythemia.

• #86 Thrombocytosis – LEVY Health

  https://levy.health/resource-center/lexicon/thrombocytosis/

  You should bring your platelet count to a healthy level before conceiving to raise your chances of a healthy pregnancy. Your treatment plan will depend on if you have essential thrombocythemia or reactive thrombocytosis. […] The treatment for women with essential thrombocythemia usually includes aspirin and/or interferon-alpha to normalize the platelet count. Speak with your doctor about the best course of action for you. For women with reactive thrombocytosis, the treatment should be directed at what is causing the high platelet count. Iron supplementation may restore balance to platelet levels in women with inflammatory bowel disease and iron deficiency. Aspirin may be prescribed to women with very high platelet counts to reduce the risk of stroke and thrombosis. […] During pregnancy, treatment with anticoagulant medication (blood thinners) such as aspirin may help prevent blood clots and improve the chances of a successful pregnancy.

• #87 Thrombocytosis – LEVY Health

  https://levy.health/resource-center/lexicon/thrombocytosis/

  You should bring your platelet count to a healthy level before conceiving to raise your chances of a healthy pregnancy. Your treatment plan will depend on if you have essential thrombocythemia or reactive thrombocytosis. […] The treatment for women with essential thrombocythemia usually includes aspirin and/or interferon-alpha to normalize the platelet count. Speak with your doctor about the best course of action for you. For women with reactive thrombocytosis, the treatment should be directed at what is causing the high platelet count. Iron supplementation may restore balance to platelet levels in women with inflammatory bowel disease and iron deficiency. Aspirin may be prescribed to women with very high platelet counts to reduce the risk of stroke and thrombosis. […] During pregnancy, treatment with anticoagulant medication (blood thinners) such as aspirin may help prevent blood clots and improve the chances of a successful pregnancy.

• #88 Essential Thrombocythemia – Hematology and Oncology – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/essential-thrombocythemia

  Sometimes aspirin […] Platelet-lowering medications (eg, pegylated interferon, anagrelide) […] Rarely plateletpheresis […] Rarely cytotoxic agents such as hydroxyurea […] Rarely stem cell transplantation. Aspirin 81 mg orally once a day is usually sufficient for mild vasomotor symptoms (eg, headache, mild digital ischemia, erythromelalgia) in low-risk patients (without cardiovascular disease) who do not have the JAK2 mutation, but a higher dose may be used if necessary. JAK2 inhibitors such as ruxolitinib may be effective for the treatment of essential thrombocythemia. Drugs used to lower platelet count include anagrelide, interferon alfa-2b, and hydroxyurea. Hydroxyurea should be prescribed only by specialists familiar with its use and monitoring and never for long-term use. Because anagrelide and hydroxyurea cross the placenta, they are not used during pregnancy; pegylated interferon alfa-2a can be used in pregnant women when necessary. Ruxolitinib, added to the best available therapy, may be effective in essential thrombocythemia

• #89 Thrombocytosis – LEVY Health

  https://levy.health/resource-center/lexicon/thrombocytosis/

  You should bring your platelet count to a healthy level before conceiving to raise your chances of a healthy pregnancy. Your treatment plan will depend on if you have essential thrombocythemia or reactive thrombocytosis. […] The treatment for women with essential thrombocythemia usually includes aspirin and/or interferon-alpha to normalize the platelet count. Speak with your doctor about the best course of action for you. For women with reactive thrombocytosis, the treatment should be directed at what is causing the high platelet count. Iron supplementation may restore balance to platelet levels in women with inflammatory bowel disease and iron deficiency. Aspirin may be prescribed to women with very high platelet counts to reduce the risk of stroke and thrombosis. […] During pregnancy, treatment with anticoagulant medication (blood thinners) such as aspirin may help prevent blood clots and improve the chances of a successful pregnancy.

• #90 Treatment of Thrombocythemia and Thrombocytosis | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-thrombocythemia-and-thrombocytosis/treatment-thrombocythemia

  Currently, hydroxyurea plus aspirin is the standard treatment for people who have primary thrombocythemia and are at high risk for blood clots. […] Anagrelide. This medicine also has been used to lower platelet counts in people who have thrombocythemia. However, research shows that when compared with hydroxyurea, anagrelide has worse outcomes. […] Interferon alfa. This medicine lowers platelet counts, but 20 percent of patients can’t handle its side effects. […] Doctors may prescribe this medicine to pregnant women who have primary thrombocythemia because it’s safer for a fetus than hydroxyurea and anagrelide. […] Plateletpheresis (PLATE-let-fe-REH-sis) is a procedure used to rapidly lower your platelet count. This procedure is used only for emergencies. […] One or two procedures might be enough to reduce your platelet count to a safe level. […] Secondary thrombocytosis is treated by addressing the condition that’s causing it. […] People who have secondary thrombocytosis usually don’t need platelet-lowering medicines or procedures.

• #91 Essential thrombocythaemia (ET) treatment and side effects | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/essential-thrombocythaemia-et/et-treatment-side-effects/

  Anagrelide is a drug treatment that’s usually recommended after you have tried at least one other treatment. […] Busulfan is usually only used when other drugs have stopped working or aren’t suitable for you. […] Clinical trials are research projects that test new drugs or combinations of drugs on people. […] Treatment for ET can cause unwanted side effects. […] Some treatments may increase the chance of ET developing into a different type of blood cancer. […] Some drugs such as hydroxycarbamide can affect your ability to have children, whether you are female or male. […] It is possible to have treatment for ET while you are pregnant. Aspirin or clopidogrel are safe to take and are standard treatments if your risk of blood clots is low.

• #92 Essential thrombocythaemia (ET) treatment and side effects | Blood Cancer UK

  https://bloodcancer.org.uk/understanding-blood-cancer/essential-thrombocythaemia-et/et-treatment-side-effects/

  Anagrelide is a drug treatment that’s usually recommended after you have tried at least one other treatment. […] Busulfan is usually only used when other drugs have stopped working or aren’t suitable for you. […] Clinical trials are research projects that test new drugs or combinations of drugs on people. […] Treatment for ET can cause unwanted side effects. […] Some treatments may increase the chance of ET developing into a different type of blood cancer. […] Some drugs such as hydroxycarbamide can affect your ability to have children, whether you are female or male. […] It is possible to have treatment for ET while you are pregnant. Aspirin or clopidogrel are safe to take and are standard treatments if your risk of blood clots is low.

• #93 Thrombocytosis – LEVY Health

  https://levy.health/resource-center/lexicon/thrombocytosis/

  You should bring your platelet count to a healthy level before conceiving to raise your chances of a healthy pregnancy. Your treatment plan will depend on if you have essential thrombocythemia or reactive thrombocytosis. […] The treatment for women with essential thrombocythemia usually includes aspirin and/or interferon-alpha to normalize the platelet count. Speak with your doctor about the best course of action for you. For women with reactive thrombocytosis, the treatment should be directed at what is causing the high platelet count. Iron supplementation may restore balance to platelet levels in women with inflammatory bowel disease and iron deficiency. Aspirin may be prescribed to women with very high platelet counts to reduce the risk of stroke and thrombosis. […] During pregnancy, treatment with anticoagulant medication (blood thinners) such as aspirin may help prevent blood clots and improve the chances of a successful pregnancy.

• #94 Thrombocytosis – LEVY Health

  https://levy.health/resource-center/lexicon/thrombocytosis/

  You should bring your platelet count to a healthy level before conceiving to raise your chances of a healthy pregnancy. Your treatment plan will depend on if you have essential thrombocythemia or reactive thrombocytosis. […] The treatment for women with essential thrombocythemia usually includes aspirin and/or interferon-alpha to normalize the platelet count. Speak with your doctor about the best course of action for you. For women with reactive thrombocytosis, the treatment should be directed at what is causing the high platelet count. Iron supplementation may restore balance to platelet levels in women with inflammatory bowel disease and iron deficiency. Aspirin may be prescribed to women with very high platelet counts to reduce the risk of stroke and thrombosis. […] During pregnancy, treatment with anticoagulant medication (blood thinners) such as aspirin may help prevent blood clots and improve the chances of a successful pregnancy.

• #95 Thrombocytosis – LEVY Health

  https://levy.health/resource-center/lexicon/thrombocytosis/

  Getting regular checkups during pregnancy can also help reduce the risk of complications. Women with thrombocytosis are recommended to have close monitoring by a hematologist (specialist in blood disorders) and gynecologist. […] If necessary, intrauterine insemination with minimal hormonal stimulation is recommended for women with this condition.

• #96

  https://haematologica.org/article/view/6991

  Thrombocytosis is now a common finding on the complete blood count (CBC) of children. […] Management and clinical outcomes in adults have been well delineated with defined recommendations for risk stratification and treatment. This is not the case for pediatric patients, for whom there is neither a standard approach to workup nor any consensus regarding management. […] The bulk of available data on the management of primary thrombocytosis comes from treatment of adult patients with ET. The hallmark of treatment for ET in adults is based on risk stratification for thrombosis. […] Treatment approaches adopted for primary thrombocytosis in children have been reported but there are no consensus guidelines. […] A recent article by Barbui described his recommendations for treatment of children and young adults with ET or PV.

• #97

  https://link.springer.com/article/10.1007/s00277-021-04485-0

  Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. […] However, data on childhood thrombocytosis are rare, and no consensus guidelines for pediatric thrombocytosis exist. […] Current literature has highlighted differences in the epidemiology and molecular pathogenesis of childhood thrombocytosis as compared to adults. […] Here we summarize literature on classification, diagnostics, and clinical management of childhood thrombocytosis. […] The present paper therefore aimed to review the specific characteristics of thrombocytosis in children and adolescents with regard to classification, diagnostic approach, and therapy. […] However, whereas guidelines for a risk-adapted therapy are available for adults affected by ET, there are no consensus recommendations tailored to the pediatric population.

• #98

  https://link.springer.com/article/10.1007/s00277-021-04485-0

  The occurrence of thromboembolic complications, one of the major concerns in persistent thrombocytosis, is far more common in primary than in secondary thrombocytosis. […] Therefore, in the absence of additional risk factors, secondary thrombocytosis in otherwise healthy children does not warrant specific treatment, and therapy is directed at the underlying causes. […] Kucine et al. proposed cytoreductive treatment for the ET high-risk group comprising children who failed low-risk therapy and those with a history of thrombosis or severe hemorrhage. […] However, in adults, ELN recommendations only suggest cytoreductive treatment if platelet counts exceed 1500109/l. […] The use of international registries may thus serve as a second-best alternative to obtain clinically useful data. […] For the time being, the use of cytoreductive therapy in childhood thrombocytosis should remain as restrictive as possible.

• #99

  https://link.springer.com/article/10.1007/s00277-021-04485-0

  The occurrence of thromboembolic complications, one of the major concerns in persistent thrombocytosis, is far more common in primary than in secondary thrombocytosis. […] Therefore, in the absence of additional risk factors, secondary thrombocytosis in otherwise healthy children does not warrant specific treatment, and therapy is directed at the underlying causes. […] Kucine et al. proposed cytoreductive treatment for the ET high-risk group comprising children who failed low-risk therapy and those with a history of thrombosis or severe hemorrhage. […] However, in adults, ELN recommendations only suggest cytoreductive treatment if platelet counts exceed 1500109/l. […] The use of international registries may thus serve as a second-best alternative to obtain clinically useful data. […] For the time being, the use of cytoreductive therapy in childhood thrombocytosis should remain as restrictive as possible.

• #100

  https://haematologica.org/article/view/6991

  Our suggested algorithm, which requires validation, selects treatments based on clinical symptoms and risk of thrombotic complications, and tailors therapy as appropriate. […] Currently a phase I Childrens Oncology Group study of ruxolitinib is underway for pediatric patients with MPN and certain malignancies. This will likely provide valuable treatment-related data for children with ET even if they are not JAK2-mutated.

• #101 What Is Thrombocytosis? | Carda Health

  https://www.cardahealth.com/post/what-is-thrombocytosis

  Once thrombocytosis is diagnosed, appropriate treatment and management strategies can be implemented to address the condition and minimize the risk of complications. The treatment and management of thrombocytosis depend on several factors, including the underlying cause, the severity of symptoms, and the risk of complications. […] The following treatment options may be considered: […] Medications can be prescribed to help control platelet production and prevent the formation of blood clots. Commonly used medications for thrombocytosis include hydroxyurea, anagrelide, and interferon. […] In certain cases of severe thrombocytosis or when there is an urgent need to rapidly reduce the platelet count, plateletpheresis may be performed. This procedure can quickly lower the platelet count and alleviate symptoms. […] If thrombocytosis is secondary to an underlying condition, the primary focus of treatment is on managing and treating the underlying cause. This often involves collaborating with specialists in the respective fields, such as hematologists or oncologists, to develop a comprehensive treatment plan.

• #102 Secondary Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560810/

  Thrombocytosis, or thrombocythemia, occurs when the platelet count exceeds 450,000/L of blood. […] Treatment focuses on addressing the underlying cause, which typically resolves the elevated platelet count. Antiplatelet therapy is generally unnecessary unless the platelet count is extremely high or there is a risk of thrombosis. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. […] Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #103 Thrombocytosis medical therapy – wikidoc

  https://www.wikidoc.org/index.php/Thrombocytosis_medical_therapy

  Often, no treatment is required or necessary for reactive thrombocytosis. […] However, in primary thrombocytosis, if platelet counts are over 750,000 or 1,000,000, and especially if there are other risk factors for thrombosis. Aspirin at low doses is thought to be protective, and extreme levels are treated with hydroxyurea (a cytoreducing agent). The new agent anagrelide (Agrylin) has recently been introduced for the treatment of essential thrombocytosis. […] Bleeding should prompt discontinuation of platelet poisons. The patient should also be worked up for DIC. Acquired Factor V deficiency or von Willebrand disease can be seen in association with extreme thrombocytosis and is managed with factor replacement, fresh frozen plasma and/or platelet apheresis coupled with a platelet lowering agent (Hydrea or anagrelide). […] Immediate platelet apheresis and a platelet lowering agent are advised for those with counts 800K.

• #104 Secondary Thrombocytosis Treatment & Management: Medical Care, Long-Term Monitoring

  https://emedicine.medscape.com/article/206811-treatment

  The primary treatment of secondary thrombocytosis (reactive thrombocytosis) should address the underlying cause of the thrombocytosis. For example, iron supplementation may normalize platelet counts in patients with thrombocytosis secondary to inflammatory bowel disease. […] In general, no treatment is indicated to directly reduce the platelet count. […] However, for patients with platelet counts in excess of 1,000,000/L, daily low-dose aspirin may be considered to minimize the rare development of stroke or thrombosis. […] A case report describes effective use of plateletpheresis for treatment of an internal carotid artery thrombus resulting in a right middle cerebral artery stroke, in a patient with previously undiagnosed reactive thrombocytosis (platelet count of 1,014,000/L) secondary to iron deficiency anemia. […] In patients with secondary thrombocytosis (reactive thrombocytosis) for whom the causal condition has not been identified, maintain careful outpatient monitoring with physical examination and routine laboratory tests to exclude the development of an occult disorder (eg, malignancy).

• #105 Secondary Thrombocytosis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK560810/

  Thrombocytosis, or thrombocythemia, occurs when the platelet count exceeds 450,000/L of blood. […] Treatment focuses on addressing the underlying cause, which typically resolves the elevated platelet count. Antiplatelet therapy is generally unnecessary unless the platelet count is extremely high or there is a risk of thrombosis. […] Secondary thrombocytosis resolves with treatment of the underlying etiology. Therefore, appropriate management should be initiated once the reactive condition, the causative factor, has been identified. […] Antiplatelet treatments, such as aspirin, are generally not indicated in secondary thrombocytosis due to the very low risk of thrombosis. However, antithrombotic therapy may be considered for patients with platelet counts exceeding 1,000,000/L, those experiencing complications from thrombocytosis, or those at risk of developing such complications. […] Plateletpheresis may be considered for patients with evidence of thrombosis or active bleeding; although its effects are temporary, it can rapidly reduce platelet counts.

• #106 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Treatment for essential thrombocytosis (primary thrombocythemia) is aimed at preventing complications and alleviating symptoms; it does not necessarily prolong survival or slow disease progression. It should be individualized on the basis of risk factors for thrombosis or bleeding. Risk factors include the following: […] Lifestyle modifications should be recommended for all patients with reversible risk factors. These include diet and exercise to promote weight loss for obese patients and smoking cessation for smokers. […] The IPSET-thrombosis risk calculator may be used for risk stratification. It stratifies patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories. […] Observation may be appropriate for very-low-risk patients (ie, those lacking any of the above risk factors), although once-daily aspirin may be used in those with cardiovascular risk factors or symptoms.

• #107 Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-017-0041-8

  At present, there is no evidence from prospective controlled studies to guide treatment recommendations for each one of the above-mentioned four risk categories in ET. […] Therefore, it is reasonable to consider further optimization of aspirin therapy in such patients by following twice-daily rather than once-daily schedule, especially in the presence of CV risk factors. […] Regardless, management of traditionally high-risk ET has been primarily guided by results of a randomized study of hydroxyurea vs no cytoreductive treatment, in high-risk patients, with the goal of keeping the platelet count below 60010(9)/L; the study showed a statistically significant benefit for hydroxyurea therapy (thrombosis rate of 3.6 vs 24%). […] Accordingly, hydroxyurea, combined with once-daily aspirin therapy, remains the standard of care for contemporarily classified high-risk patients.

• #108 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #109 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  In those who have intermediate-risk essential thrombocytosis, I do aspirin and of course modification of cardiovascular risk factors. The use of cytoreductive therapy, typically hydroxyurea, is a decision that I base on other indications for the use of cytoreductive therapies. […] When it comes to high-risk essential thrombocytosis, using an aspirin and modifying cardiovascular risk factors are of course key, but cytoreductive therapy is definitely recommended in this group of patients. The first-line treatment that we use, especially in the United States, is hydroxyurea. […] For patients who are resistant or refractory to hydroxyurea use or, for example have an intolerance in the form of adverse events like ulcers or anemia, there are a few other options. One is anagrelide, which is a quinolone inhibitor that reduces the platelet count by inhibiting megakaryocytic differentiation.

• #110 Essential Thrombocytosis Treatment & Management: Approach Considerations, Cytoreductive Therapy, Surgical Care

  https://emedicine.medscape.com/article/206697-treatment

  Low-risk patients (ie, those whose only risk factor is JAK2 or MPL mutation) can be treated with daily low-dose aspirin therapy. In those with risk factors or with persistent symptoms, low-dose aspirin can be given twice daily, although the total daily dosage should not surpass 100 mg. Cytoreductive agents are not first-line therapy due to their potential adverse effects; outcomes are otherwise similar between cytoreduction and aspirin therapy. […] Intermediate-risk patients may benefit from both aspirin and cytoreductive agents (eg hydroxyurea). Selection of treatment should be individualized on the basis of considerations including symptom burden, cardiovascular risks, and patient preference. […] High-risk patients benefit from both aspirin and cytoreductive agents (see next section for further discussion on these agents).

• #111 The Treatment Spectrum in Essential Thrombocythemia

  https://www.onclive.com/view/the-treatment-spectrum-in-essential-thrombocythemia

  Pankit Vachhani, MD: When I approach treatment for essential thrombocytosis, I keep in mind that there is no single drug or agent that that improves survival. My treatment goals are directed toward the mitigation of the thrombosis risk that these patients have. Also, there is no drug available that slows the progression of essential thrombocytosis to plastic-phase disease or overt myelofibrosis. My general approach to the treatment of essential thrombocytosis is thrombosis risk-adapted management, which largely follows the 4 risk categories found in the revised IPSET [International Prognostic Score for Thrombosis in Essential Thrombocythemia] stratification. […] For low-risk patients I suggest a daily aspirin but no cytoreductive therapy for very low-risk or low-risk patients. The caveat is that if patients present with a very high platelet count, lets say 1.5 million per mm3 or more or they have symptoms, I guide my treatment choice of cytoreductive therapy in those scenarios based on whether they meet certain indication for cytoreductive therapy.

• #112 Thrombocytosis: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/13350-thrombocytosis

  Your provider may recommend a few treatment options if you have essential thrombocythemia and are experiencing symptoms: […] Taking a daily low-dose aspirin: You can take a daily aspirin to prevent blood clots. The low dose doesnt usually cause stomach upset or bleeding. Be sure to check with your provider before taking aspirin regularly. […] Taking medicines that lower platelet levels: Medications such as hydroxyurea (Droxia, Hydrea, Siklos, Mylocel) and anagrelide (Agrilyn) suppress platelet production in your bone marrow. Interferon alfa (Multiferon) prevents abnormal platelets from dividing and multiplying. […] Having a procedure to remove your platelets: If your platelets are so high that theyre putting you at risk of life-threatening blood clots, your provider may recommend plateletpheresis. This procedure uses a machine to filter excess platelets from your blood. Most causes of thrombocytosis dont require plateletpheresis. […] Theres no cure for essential thrombocytosis, but your healthcare provider can help you manage the condition to reduce your risk of clots. High platelet levels associated with secondary causes usually return to normal once the underlying condition resolves.

• #113 Thrombocytosis in the ED – emDocs

  https://www.emdocs.net/thrombocytosis-in-the-ed/

  Treatment includes: Anticoagulation with low molecular weight heparin. NOAC’s should be avoided due to lack of data in myeloproliferative neoplasms and potential for drug interactions with JAK inhibitors. Cytoreductive agent (see table below), with platelet goal <400,000/microL. ASA 81mg daily. Immediate platelet apheresis if platelets >800,000/microL. […] Given the relatively high incidence of thrombotic complications in essential thrombocythemia, high-risk, asymptomatic patients should be treated prophylactically with antiplatelet agents + cytoreductive agents. Essential thrombocythemia patients with acute thrombotic complications require treatment with a cytoreductive agent, anticoagulation, aspirin, and possibly apheresis.

• #114 https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  https://www.lls.org/myeloproliferative-neoplasms/essential-thrombocythemia/treatment

  This is a process that uses a special machine to skim platelets from a patients blood and then return the remaining blood components to the patient. […] Taking part in a clinical trial may be the best treatment choice for some ET patients. […] Every patients medical situation is different and should be evaluated individually by a hematologist-oncologist who specializes in treating blood cancers.

• #115

  https://www.rgare.com/knowledge-center/article/reactive-thrombocytosis-a-benign-entity

  Thrombocytosis, a condition defined as having a platelet count of more than 450,000 per microliter of blood (450 x 109/L), can be either physiologic in nature or due to primary or secondary causes. […] Secondary or reactive thrombocytosis (RT) is far more prevalent than primary or clonal thrombocytosis, and the presence of comorbid conditions in RT, a transient rise in platelets, and lack of genetic mutations favor a secondary etiology. […] Therefore, it is essential for an underwriter to identify RT, as RT is not always a benign entity, which means outcomes can vary. […] This article will focus on RT, which is the most common cause of thrombocytosis. […] Given that the overall risk of thrombosis is considered to be low in RT, treatment with anti-platelet therapy such as aspirin is usually not indicated. Still, treatment can be considered for patients with platelets of 1 million/microL with complications of thrombocytosis, or for patients at risk of developing such complications. […] RT is associated with higher mortality in acutely ill patients. […] Elevated platelets are associated with worse outcomes in individuals hospitalized with COVID-19.

Zobacz więcej